Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Abstract Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to it...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-024-00616-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102124960022528 |
|---|---|
| author | Fuping Wang Longxin Chen Limeng Zhang Siyu Du Yingying Feng |
| author_facet | Fuping Wang Longxin Chen Limeng Zhang Siyu Du Yingying Feng |
| author_sort | Fuping Wang |
| collection | DOAJ |
| description | Abstract Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to its resistance to treatment. The main cause of death in MF patients is leukemic transformation. Leukemic transformation requires genetic mutations, such as the JAK2 V617F mutation, which is present in most sAML patients. Mutations in TP53 or the amplification of genes that negatively regulate p53 occur more frequently in sAML than in de novo acute myeloid leukemia (AML). Currently, the treatment of sAML poses a substantial challenge to the medical community. This review explored the potential of targeting JAK2 and MDM2 for the treatment of secondary AML caused by myelofibrosis. This review describes the research on sAML in relation to JAK2 and p53, outlines the interaction between JAK2, p53, mtP53, and MDM2, summarizes the effectiveness of JAK2 and MDM2 inhibitors, and advocates a combined approach using JAK2 and MDM2 inhibitors as a potential treatment strategy for sAML evolving from myelofibrosis. Inhibition of JAK2 and MDM2 may help improve the specificity and efficiency of sAML treatment and address drug resistance. |
| format | Article |
| id | doaj-art-6ff2c62ddad8422a8e364703b1ebf802 |
| institution | DOAJ |
| issn | 2090-2441 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj-art-6ff2c62ddad8422a8e364703b1ebf8022025-08-20T02:39:50ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412024-12-0125111010.1186/s43042-024-00616-0Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosisFuping Wang0Longxin Chen1Limeng Zhang2Siyu Du3Yingying Feng4Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Sciences, Hangzhou Institute for Advanced Study, University of Chinese Academy of SciencesMolecular Biology Laboratory, Zhengzhou Normal UniversityMolecular Biology Laboratory, Zhengzhou Normal UniversityMolecular Biology Laboratory, Zhengzhou Normal UniversityMolecular Biology Laboratory, Zhengzhou Normal UniversityAbstract Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to its resistance to treatment. The main cause of death in MF patients is leukemic transformation. Leukemic transformation requires genetic mutations, such as the JAK2 V617F mutation, which is present in most sAML patients. Mutations in TP53 or the amplification of genes that negatively regulate p53 occur more frequently in sAML than in de novo acute myeloid leukemia (AML). Currently, the treatment of sAML poses a substantial challenge to the medical community. This review explored the potential of targeting JAK2 and MDM2 for the treatment of secondary AML caused by myelofibrosis. This review describes the research on sAML in relation to JAK2 and p53, outlines the interaction between JAK2, p53, mtP53, and MDM2, summarizes the effectiveness of JAK2 and MDM2 inhibitors, and advocates a combined approach using JAK2 and MDM2 inhibitors as a potential treatment strategy for sAML evolving from myelofibrosis. Inhibition of JAK2 and MDM2 may help improve the specificity and efficiency of sAML treatment and address drug resistance.https://doi.org/10.1186/s43042-024-00616-0Secondary acute myeloid leukemiaMyelofibrosisJAK2P53Targeted therapies |
| spellingShingle | Fuping Wang Longxin Chen Limeng Zhang Siyu Du Yingying Feng Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis Egyptian Journal of Medical Human Genetics Secondary acute myeloid leukemia Myelofibrosis JAK2 P53 Targeted therapies |
| title | Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| title_full | Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| title_fullStr | Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| title_full_unstemmed | Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| title_short | Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| title_sort | inhibition of jak2 and mdm2 to treat secondary acute myeloid leukemia evolving from myelofibrosis |
| topic | Secondary acute myeloid leukemia Myelofibrosis JAK2 P53 Targeted therapies |
| url | https://doi.org/10.1186/s43042-024-00616-0 |
| work_keys_str_mv | AT fupingwang inhibitionofjak2andmdm2totreatsecondaryacutemyeloidleukemiaevolvingfrommyelofibrosis AT longxinchen inhibitionofjak2andmdm2totreatsecondaryacutemyeloidleukemiaevolvingfrommyelofibrosis AT limengzhang inhibitionofjak2andmdm2totreatsecondaryacutemyeloidleukemiaevolvingfrommyelofibrosis AT siyudu inhibitionofjak2andmdm2totreatsecondaryacutemyeloidleukemiaevolvingfrommyelofibrosis AT yingyingfeng inhibitionofjak2andmdm2totreatsecondaryacutemyeloidleukemiaevolvingfrommyelofibrosis |